Polymeric micelles as potent islet amyloid inhibitors: Current advances and future perspectives

Jaskiran Kaur; Monica Gulati; Indu Pal Kaur; Vandana Patravale; Kamal Dua; Sachin Kumar Singh

doi:10.1016/j.drudis.2023.103571

Polymeric micelles as potent islet amyloid inhibitors: Current advances and future perspectives

Drug Discov Today. 2023 May;28(5):103571. doi: 10.1016/j.drudis.2023.103571. Epub 2023 Mar 27.

Authors

Jaskiran Kaur¹, Monica Gulati², Indu Pal Kaur³, Vandana Patravale⁴, Kamal Dua⁵, Sachin Kumar Singh⁶

Affiliations

¹ School of Pharmaceutical Sciences, Lovely Professional University, Jalandhar-Delhi G.T. Road, Phagwara, Punjab 144411, India.
² School of Pharmaceutical Sciences, Lovely Professional University, Jalandhar-Delhi G.T. Road, Phagwara, Punjab 144411, India; Faculty of Health, Australian Research Centre in Complementary and Integrative Medicine, University of Technology Sydney, Ultimo, NSW 2007, Australia.
³ University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh 160014, India.
⁴ Department of Pharmaceutical Sciences and Technology, Institute of Chemical Technology, Matunga, Mumbai, Maharashtra 400019, India.
⁵ Faculty of Health, Australian Research Centre in Complementary and Integrative Medicine, University of Technology Sydney, Ultimo, NSW 2007, Australia; Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, Ultimo, NSW 2007, Australia; Uttaranchal Institute of Pharmaceutical Sciences, Uttaranchal University, Dehradun, India.
⁶ School of Pharmaceutical Sciences, Lovely Professional University, Jalandhar-Delhi G.T. Road, Phagwara, Punjab 144411, India; Faculty of Health, Australian Research Centre in Complementary and Integrative Medicine, University of Technology Sydney, Ultimo, NSW 2007, Australia. Electronic address: sachin.16030@lpu.co.in.

PMID: 36990145
DOI: 10.1016/j.drudis.2023.103571

Abstract

Diabetes mellitus (DM) has become one of the most prevalent diseases across the globe, mainly because of the inability of existing treatment strategies to target its root cause (i.e., pancreatic β cell damage). Polymeric micelles (PMs) have gained attention as a treatment option for DM by targeting misfolded islet amyloid polypeptide protein (IAPP), which is common in more than 90% of DM patients. Such misfolding could result from either oxidative stress or mutation in the gene encoding IAPP. In this review, we discuss progress in the designing of PMs to halt islet amyloidosis along with their mechanism and dynamics of interactions with IAPP. We also discuss the clinical challenges associated with the translation of PMs as anti-islet amyloidogenic agents.

Keywords: diabetes; functional chemistry; islet amyloidosis; micelles; therapeutics.

Publication types

Review

MeSH terms

Amyloid / genetics
Diabetes Mellitus, Type 2* / metabolism
Humans
Islet Amyloid Polypeptide / genetics
Islet Amyloid Polypeptide / metabolism
Islets of Langerhans* / metabolism
Micelles

Substances

Micelles
Amyloid
Islet Amyloid Polypeptide